Company News
Wockhardt Receives US FDA Approval for ZAYNICH Antibiotic
Wockhardt obtained US FDA approval for ZAYNICH™, a novel intravenous antibiotic for complicated urinary tract infections.
Phase 3 trial showed 89.0% composite success rate versus 68.4% for meropenem,
